Corvus Pharmaceuticals, Inc. (CRVS)
↓ Download CSVKey ratios (FY2025)
-25.0%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -$38.63M | -$43.76M | -$48.85M | -$49.22M | -$56.52M | -$36.98M |
| Net Income | -$15.28M | -$62.29M | -$27.03M | -$41.31M | -$43.24M | -$6.00M | -$46.67M | -$46.94M | -$55.66M | -$36.38M |
| EPS (Diluted) | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 | $-1.59 | — | — | — |
| Total Assets | $71.12M | $68.91M | $45.55M | $68.24M | $109.45M | $85.53M | $83.65M | $118.23M | $94.78M | $140.15M |
| Total Liabilities | $9.91M | $36.34M | $6.87M | $12.12M | $12.29M | $13.38M | $12.54M | $7.90M | $9.94M | $7.35M |
| Shareholders' Equity | $61.20M | $32.57M | $38.68M | $56.12M | $97.16M | $72.15M | $71.11M | $110.34M | $84.83M | $132.80M |
| Cash & Equivalents | $4.58M | $8.74M | $12.62M | $13.16M | $63.46M | $16.45M | $5.15M | $39.20M | $45.11M | $5.05M |
| Operating Cash Flow | -$32.80M | -$25.42M | -$23.93M | -$27.02M | -$36.72M | -$34.78M | -$37.32M | -$40.99M | -$46.21M | -$27.86M |
| Capital Expenditures | $174.0K | — | $34.0K | $269.0K | $5.0K | $76.0K | $25.0K | $355.0K | $266.0K | $2.20M |
| Shares Outstanding | 74.70M | 67.90M | 49.04M | 46.55M | 46.55M | 28.37M | 27.95M | 29.32M | 21.04M | 20.92M |